The 22nd and 23rd May it will be celebrated the IV Poultry Health Course organized by the Centro de Calidad Avícola y Alimentación Animal de la Comunidad de Valencia (CECAV) and the Universidad CEU Cardenal Herrera.
iMICROQ participates in the Course making a presentation entitled “Fast Salmonella determination method” and presenting the QFast Salmonella Kit.
The fourth edition of the Poultry Health Course is focused on Diagnosis and Prevention tools. During the course were held conferences on quality systems, diagnostics, epidemiology and environmental control. Also it will be conducted workshops on poultry necropsies and embriodiagnostics.
The agreement is based on the distribution, sale and technical support of QFast detection and identification system of pathogenic agents in emerging countries.
The sectors considered in this agreement are poultry industry, cosmetics, pulp and paper, raw materials, food processing and water.
Initially, target countries of this agreement, with significant growth potential, are:
• Middle East (Saudi Arabia, United Arab Emirates, Egypt)
iMICROQ and LAYMATEC are working together on different projects mainly oriented on R&D projects oriented to give complementary solutions of common interest in the area of physical-chemical and microbiological analysis, especially in poultry, cosmetics, pulp and paper, raw materials, food processing and water.
Both companies have signed a collaboration agreement for microbiology analytical services and physical-chemical parameters, with the resources and infrastructure of LAYMATEC in geographical areas where iMicroQ operates directly. Thus, iMicroQ expands its portfolio of services to offer to its customers a comprehensive analytical service using QFAST platform and offering the traditional analytical method.
In a complementary manner, the agreement includes analytical services of physicochemical parameters for other projects that require solutions “tailored” to meet the needs and challenges that each iMicroQ client may have.
iMICROQ achieves an investment agreement to fund the industrialization and commercialization of the Kit QFast Salmonella
On April 17, 2013, iMICROQ signed the new associate agreement and capital increase to finance the development of its business.
”la Caixa”, through its venture capital agency, Caixa Capital Risc, has led an investment of 1.1 million euros in iMICROQ. The financial entity has made the investment thought its fund specialized in biotechnology and medical technologies, Caixa Capital BioMed.
In addition, a group of business angels with experience in international business development have joined the investment round.
This round of investment is aimed for accelerating international validation activities, industrial and production tests to start the international commercialization of the kit for rapid detection of Salmonella spp (QFast Salmonella).
iMICROQ participates in the Jornadas Profesionales de Avicultura (JPA 2013) organized by the Real Escuela de Avicultura in Leon from 28th to 31st May.
The congress is divided into four blocks, differentiating between poultry production and egg-laying. It will be covered different topics such as nutrition, pathology, reproduction and incubation, sustainable production systems, industry-specific issues and trends on the welfare of poultry.
In the course of the congress, iMICROQ will made a presentation entitled “Innovation in diagnostic techniques. A revolutionary approach of farm-level diagnostic: analytical micro-technology for recognition of poultry pathogen bacterial microorganisms”.
iMicroQ has visited the Salón Internacional de Producción Ganadera (FIGAN) 2013, where major international agricultural companies presented the latest technological innovations and business solutions designed to enhance the development of livestock activities and face the future of the market and industry.
A total of 836 exhibitors from twenty-five countries presented their latest developments in the eleventh edition of the Feria Internacional de la Producción Animal, that takes place from 19th to 22nd March.
The iMICROQ delegation has visited FIGAN exhibitors presenting the future market launch of the QFast Salmonella Kit, that allows an easy, fast and reliable determination of the presence or absence of Salmonella spp in primary production environments, environmental samples, eggs, meat products, animal feed and raw materials.
IMICROQ won the 1st edition of the Competition Opinno Biotech. It has also taken part as a participating company in the Investment Forum, organized in partnership with MIT Enterprise Forum. This Forum has brought together prominent business projects and a select group of venture capital investors specialised in green technologies, biotechnology / nanotechnology, as well as information and communication technologies.
EmTech is the biggest event of the Annual Technology Review, the most prestigious publication of the Massachusetts Institute of Technology (MIT). For the first time, this meeting, held for 12 years in Boston, had a replica in Europe. EmTech Spain arrives to Spain (26-27 October, Malaga), to bring together business leaders, the most important researchers and technologists, as well as the most innovative entrepreneurs to share knowledge.
Within the framework of the MIT conference EmTech Spain, innovative ideas and important projects of young Spanish scientists have been awarded through the Opinno Biotech Competition sponsored by Genome Spain and Zeltia. Thus, this competition has selected the works that have develop new technologies or new applications for existing technologies, and that represent an advance in the field of biotechnology. In addition, all participants have benefited from an Elevator Pitch to a wide number of investors, MIT academics, trend leaders, media, etc..
The selected projects have been 25 in total, of which 5 have been finalists:
- AlphaSip: company expert in the development of medical diagnostic chips, focusing its technology in the fields of haematology and cardiovascular disease. The company’s main landmark is a home-used monitoring device oriented to patients treated with oral anticoagulants.
- Ambiox Biotech: spin-off from the University of Alcala de Henares and the Gregorio Marañón Hospital in Madrid. It specializes in nanotechnology innovation and its application in the biomedicine field. Its present main objective is to stop the impact of AIDS on society with a topical gel.
- Biotech Hesperides Group S.L: first EBT at the University Pablo de Olavide. It focuses on developing innovative food and beverage from biotechnological transformation of fruits, juices, milk, etc.
- IMICROQ, Integrated Microsystems for Quality of Life S.L.
- MicruX: start-up focused on the development and commercialization of microchip capillary electrophoresis (based on lab-on-a-Chip technology), as well as instrumentation and applications for different sectors of society.
EmTech is the big event of the annual Technology Review, the most prestigious publication of the Massachusetts Institute of Technology (MIT). For the first time, this meeting, held for 12 years in Boston, has a replica in Europe. EmTech Spain arrives to Spain, 26-27 October in Malaga, to bring together business leaders, the most important researchers and technologists, as well as the most innovative entrepreneurs to share knowledge.
Within the framework of the MIT conference EmTech Spain, through the Opinno Biotech Competition, innovative ideas and important projects of young Spanish scientists have been awarded. Thus, this competition has selected the works that have develop new technologies or new applications for existing technologies, and that represent an advance in the field of biotechnology.
IMICROQ has been a finalist company in this 1st edition of the Competition Opinno Biotech. It has also debuted as a participating company in the Investment Forum, organized in partnership with MIT Enterprise Forum. This Forum has brought together prominent business projects and a select group of venture capital investor specializing in green technologies, biotechnology / nanotechnology, as well as information and communication technologies.
The 22nd of June 2011 took place the technical workshop “Control of Salmonella: future prospects: legislation and analytical techniques” organized by IMICROQ, the Aragon and Catalonia Aviary Sanitary Centre (CESAC) and the Research Centre ATIC, University Rovira i Virgili. This event was sponsored by ACC10, Agency for the Support of the Competitiveness of the Catalan Business; ITPSA S.A.: HIPRA; S.P. Veterinary S.A. Adiveter S.L.; ESTEVE Pharmaceutical Group; Anorsa S.A. y Scharlab S.L.
IMICROQ technology has been selected by Genoma España for its INNOCASH program, for the development of technical dossier, as a high economic potential proposal.
WINEQUALIMONITO within the Industrial Biotechnology Program.
The project is the answer WineQualiMonito two European SMEs in biotechnology technology, microsystems and microfluidics to provide a sensing device that allows in situ monitoring of quality control parameters of the grape that is used for wine production. This project has the participation of the Foundation Vi Technology Park, the leading industrial research center of the wine in Catalonia.
The project will develop the basic principles of an analytical device for detection and quantification of gluconic acid as a demonstrated capacity to an integrated product line that needs further monitoring of indicators of quality for wine production.
Recognition of the best business plan
El plan de negocios de IMICROQ ha sido premiado por:
- the Tarragona City Council as the best business plan (2009),
- the Reus City Council, Redessa award, as the best business plan (2010),
- the Barcelona City Council, Barcelona Activa, with the 2nd prize of Bio-entrepreneurs S.XXI.
These resources have been invested in the company.
- Electrochemical detection of absence/presence in a quantitative way.
- Expected LOD of 1 UFC/25 g of initial sample.
- Total time of detection, once the sample is taken, of less than 14 hours.
- Objective world-wide market in agri-food security of 2.400 M€/year.
IMICROQ specializes in the development of a rapid detection kit, for the quantitative detection of Salmonella that would reduce the total time of detection since the sample is taken until there is a reliable measurement, thus focus on the manufacturing line.
Once validated this detection kit, thus compared to the reference method ISO 6579:2002, an AFNOR and/or AOAC certification will be sought.
The kits portfolio for the food industry will be complemented with the detection of Campylobacter, as well as PCR products for the serotyping of Campylobacter and Salmonella and other bacteria, thus having a multidetection pathogen platform.
2 Multipath, projects within HEALTH.2011 program of the European Union to develop an analytical test MDCT.
Advanced MULTIPAHT exploits the science of micro, nano and bio-technologies to create a low-cost diagnostic microsystem, which is addressed in the implementation of the rapid identification of pathogenic infection unknown bacteria in a clinical setting via immunomagnetic isolation and detection sensors.
The exploitation of micro parallel with the determination of antibiotic susceptibility, monitoring the dynamics not only provide quantitative information on resistance patterns and antibiotic susceptibility of the patient but also will determine the severity of the infection with antibiotic doses required. In parallel, the integrated microsystem, the molecular identification of the serotype of bacteria will be done through a combination of multicameras and multianalyte detection using an array of geno-sensors.
An alternative, more economic microsystem will be developed for cases where the source of infection is known and in which the capture of bacteria cells will undergo a rapid parallel testing of susceptibility to the antibiotic kinetics in real time. MULTIPATH platform seeks to achieve results in 4 hours, at an estimated cost of 20 – 50 € in the case of unknown bacterial infections and 8 to 10 € for cases of known bacterial infections, which distinguishes the prescription of antibiotics to patients (both type and dose) by a combination of blood cultures and molecular analysis.
3 MultiSense, projects within the program “Restoring security in case of crisis,” “Preparing for a crisis and resilience Chemical, Biological, Radiological, Nuclear”
The aim of MULTISENSE is the development of a system for detection and identification for biological pathogens, which includes both the stage of sample preparation, during which the target molecules are extracted directly and parallel steps are performed molecular or immunological detection that can build an integrated “sample entry, obtaining a result.” New technologies in sensors, optoelectronic or electrochemical ‘lab on a chip “and innovations in instrumentation are the keys to successful project outcomes to be achieved such as: portable, easy to use, with ability to perform unit operations such as sample preparation, extraction of the target molecules in a micro-plate with all the necessary reagents incorporated.
This includes storing dry reagents for analysis, master prepared for PCR, antibody and buffer liquid storage solutions. The chip will include a waste storage tank to eliminate risks of contamination. The overall project goal is the handling procedure of detection and analysis system “sample entry, delivery of results” with a reduced processing time and the advantages of miniaturization with the combination of all biological processes disposable chip instead of having to use different instruments in a specialized laboratory. Finally, the chip will analyze suspect samples directly on the site without having to transport them to the nearest laboratory with availability for PCR or immunological tests.